Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy - A fluorescence in-situ hybridization study

Leukemia and Lymphoma

Volumn 45, Issue 8, 2004, Pages 1627-1631

  Thiele, Juergen ^a   Kvasnicka, Hans Michael ^a   Varus, Eva ^a   Ollig, Esther ^a   Schmitt Graeff, Annette ^b   Staib, Peter ^a   Griesshammer, Martin ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Bcr Abl translocation; Bone marrow biopsies; Chronic myeloid leukemia; Imatinib mesylate (STI571); Megakaryocytes

Indexed keywords

BCR ABL PROTEIN; CD61 ANTIGEN; IMATINIB;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW DISEASE; CASE REPORT; CELL LINEAGE; CELL POPULATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; HEMATOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MORPHOMETRICS; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MEGAKARYOCYTES; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TRANSLOCATION, GENETIC;

EID: 3042735581     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001683732     Document Type: Article

References (27)

1. Braziel, R.M., Launder, T.M., Druker, B.J., Olson, S.B., Magenis, R.E., Mauro, M.J., et al. (2002) "Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. PG-435-41", Blood, 100, 435-441.
2. Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., et al. (2002) "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study", Blood, 99, 1928-1937.
3. Goldman, J.M. and Druker, B.J. (2001) "Chronic myeloid leukemia: current treatment options", Blood, 98, 2039-2042.
4. Cervantes, F., Hernandez-Boluda, J.C., Steegmann, J.L., Conde, E., Alvarez-Larran, A., Lopez-Jimenez, J., et al. (2003) "Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients", Haematologica, 88, 1117-1122.
5. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine, 344, 1031-1037.
6. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., et al. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", New England Journal of Medicine, 346, 645-652.
7. O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003) "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", New England Journal of Medicine, 348, 994-1004.
8. Deininger, M.W. (2003) "Cytogenetic studies in patients on imatinib", Seminars in Hematology, 40, 50-55.
9. Beham-Schmid, C., Apfelbeck, U., Sill, H., Tsybrovsky, O., Hofler, G., Haas, O.A., et al. (2002) "Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis", Blood, 99, 381-383.
10. Hasserjian, R.P., Boecklin, F., Parker, S., Chase, A., Dhar, S., Zaiac, M., et al. (2002) "STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response", American Journal of Clinical Pathology, 117, 360-367.
11. Rumpel, M., Friedrich, T. and Deininger, M.W. (2003) "Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase", Blood, 101, 4641-4643.
12. Frater, J.L., Tallman, M.S., Variakojis, D., Druker, B.J., Resta, D., Riley, M.B., et al. (2003) "Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status", American Journal of Clinical Pathology, 119, 833-841.
13. Bartl, R., Frisch, B. and Wilmanns, W. (1993) "Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD)", European Journal of Haematology, 50, 41-52.
14. Georgii, A., Buesche, G. and Kreft, A. (1998) "The histopathology of chronic myeloproliferative diseases", Baillieres Clinical Haematology, 11, 721-749.
15. Nafe, R., Georgii, A., Kaloutsi, V., Fritsch, R.S. and Choritz, H. (1991) "Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders", Virchows Archive B, Cell Pathology Including Molecular Pathology, 61, 111-116.
16. Thiele, J., Titius, B.R., Kopsidis, C. and Fischer, R. (1992) "Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes", Virchows Archive B, Cell Pathology Including Molecular Pathology, 62, 275-282.
17. Cordell, J.L., Falini, B., Erber, W.N., Ghosh, A.K., Abdulaziz, Z., MacDonald, S., et al. (1984) "Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes ", Journal of Histochemistry and Cytochemistry, 32, 219-229.
18. Thiele, J. and Fischer, R. (1991) "Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview", Virchows Archive A, Pathological Anatomy and Histopathology, 418, 87-97.
19. Kobzev, Y., Domracheva, E., Zakharova, A., Khoroshko, N., Turkina, A. and Dewald, G. (1998) "Fluorescence in situ hybridization studies of interphase nuclei for assessing response to therapy in patients with chronic myeloid leukemia", Cancer Genetics and Cytogenetics, 106, 128-134.
20. Dewald, G.W., Wyatt, W.A., Juneau, A.L., Carlson, R.O., Zinsmeister, A.R., Jalal, S.M., et al. (1998) "Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia", Blood, 91, 3357-3365.
21. Nolte, M., Werner, M., Ewig, M., von Wasielewski, R., Wilkens, L., Link, H., et al. (1996) "Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation", Leukemia and Lymphoma, 22, 287-294.
22. Werner, M., Ewig, M., Nasarek, A., Wilkens, L., von Wasielewski, R., Tchinda, J., et al. (1997) "Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens", Diagnostic Molecular Pathology, 6, 282-287.
23. Brynes, R.K., McCourty, A., Ho, J.P., Traweek, S.T., Snyder, D.S. and Slovak, M.L. (1994) "Detection of the Philadelphia chromosome in paraffin-embedded tissue by fluorescence in situ hybridization", Modern Pathology, 7, 565-569.
24. Thiele, J., Schmitz, B., Gross, H., Kvasnicka, H.M., Niederle, N., Leder, L.D., et al. (1997) "Fluorescence in-situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon-alpha therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation", Histopathology, 31, 215-221.
25. Bentz, M., Cabot, G., Moos, M., Speicher, M.R., Ganser, A., Lichter, P., et al. (1994) "Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization", Blood, 83, 1922-1928.
26. Dewald, G.W., Schad, C.R., Christensen, E.R., Tiede, A.L., Zinsmeister, A.R., Spurbeck, J.L., et al. (1993) "The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL", Cancer Genetics and Cytogenetics, 71, 7-14.
27. Amiel, A., Yarkoni, S., Fejgin, M., Gaber, E., Nagler, A., Manor, Y., et al. (1993) "Clinical detection of BCR-abl fusion by in situ hybridization in chronic myelogenous leukemia", Cancer Genetics and Cytogenetics, 65, 32-34.